Atrium Therapeutics gets FDA clearance for ATR 1072 IND application
Atrium Therapeutics announced on July 14, 2026 that the FDA has cleared its Investigational New Drug application for ATR 1072, allowing the company to begin its Corventis™ Phase 1/2 clinical trial in patients with PRKAG2 syndrome. The trial will enroll approximately 37 participants across two parts: Part A evaluating multiple ascending doses, and Part B a single-arm expansion cohort. The company expects the first participant enrolled by end of 2026, with initial proof-of-concept data anticipated in the second half of 2027.
- FDA cleared IND application for ATR 1072 on July 14, 2026
- Corventis™ Phase 1/2 trial will enroll approximately 37 participants across two parts
- ATR 1072 uses small interfering RNA to silence mutant PRKAG2 messenger RNA
- First participant enrollment expected by end of 2026
- Initial trial data demonstrating proof of concept anticipated in second half of 2027
- PRKAG2 syndrome is a rare autosomal dominant early-onset cardiomyopathy with estimated 1,000–2,000 people in the US
- ATR 1072 is Atrium's first precision cardiology program to enter the clinic
IND clearance marks Atrium's first clinical-stage advancement in its precision RNA cardiology platform and positions ATR 1072 as the first potential treatment targeting the underlying genetic cause of PRKAG2 syndrome.
Derived from 8-K filed 2026-07-14. Not investment advice. Figures are extracted from the filing; prose is AI-assisted. View the source filing on SEC.gov →